Research graph
References from Spatial architecture of tumor-infiltrating lymphocytes adds predictive value beyond stromal TIL density for neoadjuvant response in triple-negative breast cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
10.1038/nrclinonc.2016.66 · 2016 · External reference
Triple-negative breast cancer
10.1056/nejmra1001389 · 2010 · External reference
Overall survival with pembrolizumab in early-stage triple-negative breast cancer
10.1056/nejmoa2409932 · 2024 · External reference
Event-free survival with pembrolizumab in early triple-negative breast cancer
10.1056/nejmoa2112651 · 2022 · External reference
Pembrolizumab for early triple-negative breast cancer
10.1056/nejmoa1910549 · 2020 · External reference
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
10.1016/s0140-6736(13)62422-8 · 2014 · External reference
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer
10.1200/jco.2009.23.7370 · 2010 · External reference
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers
10.1200/jco.2014.58.1967 · 2015 · External reference
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
10.1016/s1470-2045(17)30904-x · 2018 · External reference
Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers
10.1200/jco.18.01010 · 2019 · External reference
Predictive value of tumor-infiltrating lymphocytes to pathological complete response in neoadjuvant treated triple-negative breast cancers
10.1186/s13000-018-0743-7 · 2018 · External reference
Predictive roles of baseline stromal tumor-infiltrating lymphocytes and Ki-67 in pathologic complete response in an early-stage triple-negative breast cancer prospective trial
10.3390/cancers15133275 · 2023 · External reference
Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
10.1016/j.semcancer.2017.10.003 · 2018 · External reference
Assessing tumor-infiltrating lymphocytes in solid tumors: a practical review for pathologists and proposal for a standardized method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in melanoma, gastrointestinal tract carcinomas, non-small cell lung carcinoma and mesothelioma, endometrial and ovarian carcinomas, squamous cell carcinoma of the head and neck, genitourinary carcinomas, and primary brain tumors
10.1097/pap.0000000000000161 · 2017 · External reference
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
10.1093/annonc/mdu450 · 2015 · External reference
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
10.1038/nrclinonc.2015.215 · 2016 · External reference
Delineating the breast cancer immune microenvironment in the era of multiplex immunohistochemistry/immunofluorescence
10.1111/his.14328 · 2021 · External reference
Artificial intelligence-based digital scores of stromal tumour-infiltrating lymphocytes and tumour-associated stroma predict disease-specific survival in triple-negative breast cancer
10.1002/path.6061 · 2023 · External reference
Spatial characterization of tumor-infiltrating lymphocytes and breast cancer progression
10.3390/cancers14092148 · 2022 · External reference
Whole slide image features predict pathologic complete response and poor clinical outcomes in triple-negative breast cancer
10.1016/j.prp.2023.154476 · 2023 · External reference
Utilizing automated breast cancer detection to identify spatial distributions of tumor-infiltrating lymphocytes in invasive breast cancer
10.1016/j.ajpath.2020.03.012 · 2020 · External reference
Automated scoring methods for quantitative interpretation of tumour infiltrating lymphocytes (TILs) in breast cancer: a systematic review
10.1186/s12885-024-12962-8 · 2024 · External reference
Development of training materials for pathologists to provide machine learning validation data of tumor-infiltrating lymphocytes in breast cancer
10.3390/cancers14102467 · 2022 · External reference
The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably
10.1016/j.eclinm.2024.102928 · 2024 · External reference
Automated detection and scoring of tumor-infiltrating lymphocytes in breast cancer histopathology slides
10.3390/cancers15143635 · 2023 · External reference
Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement
10.1186/s12916-014-0241-z · 2015 · External reference
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
10.1136/bmj.39335.541782.ad · 2007 · External reference
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
10.1038/modpathol.2016.109 · 2016 · External reference
Decision curve analysis: a novel method for evaluating prediction models
10.1177/0272989x06295361 · 2006 · External reference
Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial
10.1001/jamaoncol.2015.0830 · 2015 · External reference
Digital image analysis and machine learning-assisted prediction of neoadjuvant chemotherapy response in triple-negative breast cancer
10.1186/s13058-023-01752-y · 2024 · External reference
Spatial predictors of immunotherapy response in triple-negative breast cancer
10.1038/s41586-023-06498-3 · 2023 · External reference
Spatial proximity of CD8(+) T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer
10.1038/s41523-025-00728-9 · 2025 · External reference
Ecotypes of triple-negative breast cancer in response to chemotherapy
10.1038/s41586-026-10469-9 · 2026 · External reference
Predictive value of tertiary lymphoid structures assessed by high endothelial venule counts in the neoadjuvant setting of triple-negative breast cancer
10.4143/crt.2016.215 · 2017 · External reference
Spatial organization and molecular correlation of tumor-infiltrating lymphocytes using deep learning on pathology images
10.1016/j.celrep.2018.03.086 · 2018 · External reference
Intratumoral heterogeneity and immune response indicators to predict overall survival in a retrospective study of HER2-borderline (IHC 2+) breast cancer patients
10.3389/fonc.2021.774088 · 2021 · External reference
A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer
10.1038/s41591-023-02643-7 · 2024 · External reference
Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge
10.1038/s41467-026-72956-x · 2026 · External reference
Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: a report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer
10.1002/path.6155 · 2023 · External reference
Report on computational assessment of tumor infiltrating lymphocytes from the International Immuno-Oncology Biomarker Working Group
10.1038/s41523-020-0154-2 · 2020 · External reference
B cells and tertiary lymphoid structures promote immunotherapy response
10.1038/s41586-019-1922-8 · 2020 · External reference
